Supplemental Table 1. Multivariate analysis showed independent factors associated with the overall survival rates of 102 patients with NSCLC.

Variables	SE	p-value	Exp (β)	95% CI for Exp (β)
Age:>67 years vs. ≤67 years	0.570	0.710	0.809	0.265 to 2.472
Sex: female vs. male	0.865	0.446	1.933	0.355 to 10.528
Height: >170 cm vs. ≤170 cm	0.705	0.778	0.820	0.206 to 3.261
Tumor size: >4.35 cm vs. ≤5.35 cm	0.558	0.312	0.569	0.191 to 1.699
CEA: >43.79 ng/mL vs. ≤43.79 ng/mL	0.566	0.030	3.424	1.130 to 10.380
CA153: >34.39 u/mL vs. ≤34.39 u/mL	0.496	0.591	1.305	0.494 to 3.447
EGFR inhibitor history: yes vs. no	0.933	0.794	0.783	0.126 to 4.878
EGFR mutation: yes vs. no	0.546	0.051	2.897	0.994 to 8.441
Lymphocyte: >19.6% vs. ≤19.6%	0.495	0.908	1.059	0.401 to 2.796
Tumor pathology: SQ vs. AD*	0.793	0.012	7.275	1.536 to 34.445
ECOG PS: 0/1/2 vs. 3	0.652	0.019	4.626	1.289 to 16.602
Tumor site: central vs. peripheral	0.907	0.035	6.796	1.148 to 40.223
Chemotherapy cycles: ≥3 vs. <3	0.694	0.176	0.391	0.101 to 1.524
Chemotherapy: yes vs. no	0.797	0.066	4.327	0.908 to 20.628
Number of tumor somatic mutations: ≥3 vs. <3	0.724	0.077	3.591	0.870 to 14.829

^*SQ, squamous cell carcinoma; AD, adenocarcinoma.

Bold values indicate significant difference.